The IGNYTE continues to show promising outcomes despite negative FDA decisions.

Daniel Olson, MD, discusses the results of a phase 1 trial of brenetasfusp, a PRAME ImmTAC therapy in advanced melanoma.

APP-led benign hematology consults boost access in community oncology—cut wait times, expand capacity, and show how teams scale safely. As community oncology practices continue to face growing patient ...

SENOMAC at ASCO 2026 shows skipping completion ALND in select breast cancer keeps survival high and cuts lymphedema, boosting ...

The AKT inhibitor ipatasertib resulted in 41% overall response rate when combined with pembrolizumab in head and neck squamous cell carcinoma. Ipatasertib, an oral pan-AKT inhibitor, resulted in ...

"Early molecular testing is critically important now in these mCSPC patients,” said TALAPRO-3 lead investigator Neeraj Agarwal, MD. Adding talazoparib to enzalutamide reduced the risk of radiographic ...

“The results support daraxonrasib as the new standard of care for patients with previously treated metastatic PDAC,” said Brian Wolpin, MD. Daraxonrasib reduced the risk of death by 60% compared with ...

Durvalumab monotherapy did not meet the prespecified statistical threshold for DFS versus active monitoring, despite a 6-point absolute 3-year DFS difference (78% vs 72%). RAMPART enrolled ...

Five-year OS was 94.4% with ALND omission vs 93.4% with completion ALND (HR 0.89), confirming non-inferiority; breast cancer–specific survival was similarly high in both arms. Inclusion of mastectomy ...

Long-term safety was stable without emergent signals; grade ≥3 TRAEs stayed ~57–59%, while cumulative neuropathy increased with duration, managed via interruptions and EV dose reductions. Notably, ...

Mixture cure modeling estimated a 54% cure fraction with dostarlimab plus carboplatin–paclitaxel vs 14% with chemotherapy alone in dMMR/MSI-H advanced/recurrent endometrial cancer. Four-year PFS ...

frontMIND randomized 899 adults (IPI 3–5; ECOG 0–2) to six 21-day cycles of tafasitamab/lenalidomide/R-CHOP vs placebo/R-CHOP, with investigator-assessed PFS as ...